Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.
about
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation studyRecent advances in understanding/management of non-alcoholic steatohepatitis.Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markersNoninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.Inflammation in nonalcoholic steatohepatitis.Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patientsNonalcoholic fatty liver disease: Diagnostic biomarkers.Fatty liver disease in children: eat now pay later.Autophagy and non-alcoholic fatty liver disease.Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease.Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis.Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.An apoptosis panel for nonalcoholic steatohepatitis diagnosisCytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.Diagnosis and evaluation of nonalcoholic fatty liver disease.Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosisCell death and cell death responses in liver disease: mechanisms and clinical relevanceThe non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitisAn Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study.The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variantsA phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Nonalcoholic steatohepatitis: risk factors and diagnosis.Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.Clinical considerations for the management of residual diabetes following bariatric surgery.The epidemiology, pathogenesis and histopathology of fatty liver disease.Nonalcoholic fatty liver disease: current issues and novel treatment approaches.Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives.New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver.Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.Cytokeratin-18 in Diagnosis of HCC in Patients with Liver CirrhosisDevelopment of an in vitro human liver system for interrogating nonalcoholic steatohepatitis.Apoptosis and diagnosis of nonalcoholic steatohepatitis.Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?
P2860
Q24657221-3A077F19-B66C-49E9-84DF-D888D0CB4F91Q28085689-F38A7ECA-A23F-47AB-BD59-A110B421B4E2Q28542723-42219DBE-13FD-4D45-9489-331E6197F295Q30432576-8CFFFCEC-0A6C-4A32-9EC9-7794C233DA29Q30453231-7D597172-403B-41F5-9228-D37040F4165EQ30464608-C62E2545-2223-4B86-8179-D8334C11CF24Q33637279-983AF49A-65E7-4540-950E-341A29D40DD4Q33706254-CB3CF416-C0C0-402A-8325-FBEB22B0436DQ33718945-0A63D6DC-FA72-4E77-977A-CB4D711D89ECQ34247340-0D1B4DE3-2951-4479-9C91-5B122BF87979Q34698815-F05B852C-BC97-4995-80B1-43EF93321F5CQ34802423-45420532-BC45-4445-8D41-49CE00CD08A8Q34830398-992BB032-F35A-4B54-87BC-02194D57434CQ34995562-A2D2145D-0506-4DD4-BA12-89FFBCF80675Q35064093-00D530B1-CD7E-4E16-8C42-E8D0FCE7B54DQ35101419-4C556BA6-6AA3-4D42-957A-DB48B4D344A4Q35495753-A7F78046-3FBA-49DA-B949-FC54B34202B5Q35674098-E24B92AF-D40B-4529-8D0F-29A61C84ECB1Q35938040-B808A127-7D26-4762-B3FA-A28F46DA1273Q35963873-26BE8A3E-482D-4E78-954E-DE5A89F23B82Q36328050-5256F332-9FF9-46CB-85B7-7983B7A90D05Q36495366-65359AD3-935F-429C-B2F8-186CA10BEBCFQ36782785-248954A7-E163-453E-B00F-679F9AD1D87DQ37189403-052CBBEC-34BD-4CD6-8F7C-E3763DF19A78Q37689828-734D2739-8A83-4F2C-91B6-D5A41D911E2DQ37798824-1FA72DB3-73CA-4D25-88E1-BE8FD9BED506Q37811071-1FC147DF-E481-4ED8-8D0F-F9D6A92437F4Q37863133-F0B5741A-3E9B-4CBB-8B47-E37BD7834329Q37979850-6F23108B-D696-44D7-B669-461AEB305198Q37988893-AEFD95FC-0841-4227-840D-39ACEC875037Q38074898-37F6D307-BC26-4230-B9A4-CE86C57B776CQ38494198-BBADC767-D1B9-47E5-ADB4-343149B4CBB4Q38720197-4CBEDE05-C43D-4289-B60A-CFAA00B84817Q38725581-4EED1391-B306-42AB-8851-1679CF677D4DQ38790052-12203973-6198-4157-98C2-51A5FC70EA86Q38974249-45205A71-16FE-48E4-9A95-901C5BC150F5Q39096520-5C81E79B-405E-40BB-AAE5-554B6C59C9C9Q39109576-6A8F77BC-69A2-451A-B81C-46CB7D3D2D9FQ42180658-589FEABB-7283-4725-AD31-5B39A695BE4AQ43092106-AD3A076A-B764-4CE3-AD05-953233989A13
P2860
Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@en
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@nl
type
label
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@en
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@nl
prefLabel
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@en
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@nl
P2093
P2860
P921
P1476
Cytokeratin 18 fragment levels ...... in bariatric surgery patients.
@en
P2093
Ariel E Feldstein
Dima L Diab
Lisa Yerian
Philip Schauer
Rocio Lopez
Sangeeta R Kashyap
Stanley L Hazen
P2860
P304
P356
10.1016/J.CGH.2008.07.016
P407
P577
2008-07-26T00:00:00Z